Kyntra Bio, Inc. (KYNB) stock analysis

KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30

$3.59−0.09 (-2.45%)

Close on Nov 12, 2026Market cap $14.54MP/E 0.1Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Weak5 of 30 checks passed

Kyntra Bio passes 5 of the 30 checks behind our score; 20 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation: 2/6
Growth: 0/6
Past performance: 2/6
Financial health: 1/6
Dividend: 0/6

What stands out

P/E below the industry
Kyntra Bio's P/E of 0.1 is below the Drugs median of 25.1.
P/S below the industry
Kyntra Bio's price-to-sales of 3.23 is below the Drugs median of 4.80 (book value is negative, so we use sales).
Net margin above its 5-year average
Net margin was 3968% over the last twelve months, against a 5-year average of 350%.
Net margin above the industry
Kyntra Bio's net margin of 3968% is above the Drugs median of -53.0%.

What to watch

Revenue growing under 10% a year
Revenue grew -64.2% a year over the last three fiscal years, short of the 10% we look for.
Interest not well covered
Operating income covers interest expense -5.4 times; we look for at least 5.
Elevated bankruptcy risk
The Altman Z-score is -24.47; above 3 is the safe zone and below 1.8 the distress zone.
Growing slower than the industry
Revenue grew -37.1% over the last twelve months; the Drugs median is 8.0%.

Valuation2/6

P/E against its history
Not enough price and earnings history to compare.
P/E below the industry
Kyntra Bio's P/E of 0.1 is below the Drugs median of 25.1.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/S below the industry
Kyntra Bio's price-to-sales of 3.23 is below the Drugs median of 4.80 (book value is negative, so we use sales).
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.

Growth0/6

Revenue growing under 10% a year
Revenue grew -64.2% a year over the last three fiscal years, short of the 10% we look for.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew -37.1% over the last twelve months; the Drugs median is 8.0%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.

Past performance2/6

Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity against the industry
Needs positive equity.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin above its 5-year average
Net margin was 3968% over the last twelve months, against a 5-year average of 350%.
Net margin above the industry
Kyntra Bio's net margin of 3968% is above the Drugs median of -53.0%.

Financial health1/6

Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt coverage
Needs operating cash flow.
Interest not well covered
Operating income covers interest expense -5.4 times; we look for at least 5.
Short-term assets cover short-term debts
Current assets are 2.69 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -24.47; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

No dividend
Kyntra Bio has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Kyntra Bio. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

P/E at month end
Drugs median 25.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day: $126.34K
Value traded per 1% price move: $40.11K

Downside

High risk

Typical loss in a bad month: 35.0%
Volatility (annualized): 57%
Sharpe ratio, 1 year: -1.25
Beta to the S&P 500 (5Y): 1.26

Typical bad-month loss, week by week

Margins

Share of revenue, fiscal years 2012 to 2025

Gross margin

91.4%−3.6 pts over 5 years

Operating margin

-712.7%−603.8 pts over 5 years

Net margin

2848.6%+2956.0 pts over 5 years

Per year	1 year	3 years	5 years	10 years	Five-year pace
Revenue	-78.3%	-64.2%	-48.4%	-28.4%
Gross profit	-58.2%	-63.4%	-48.8%	–

Returns and balance sheet

10 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2016	FY2020	FY2025
Return on equity	-34.8%	-40.3%	-143.5%
Return on assets	-12.4%	-22.5%	109.8%
Current ratio	4.09	4.63	3.39
Interest coverage	-4.7×	-79.9×	-5.2×
Inventory turnover	–	0.8×	0.2×
Capex to revenue	0.7%	2.3%	0.6%
Diluted shares	3M	4M	4M

DuPont analysis

Return on equity split into margin, efficiency and leverage

Net margin2848.6%

Asset turnover0.04×

Equity multiplier-1.31×

Return on equity, FY2025-143.5%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2025	2848.6%	0.04×	-1.31×	-143.5%
FY2024	-160.6%	0.09×	-1.48×	22.1%
FY2023	-607.3%	0.09×	-4.58×	252.0%
FY2022	-208.7%	0.20×	7.37×	-312.9%
FY2021	-123.3%	0.29×	2.54×	-91.9%
FY2020	-107.4%	0.21×	1.79×	-40.3%
FY2019	-30.0%	0.30×	1.70×	-15.0%
FY2018	-40.6%	0.24×	1.71×	-16.7%
FY2017	-92.3%	0.19×	2.00×	-35.3%
FY2016	-31.7%	0.39×	2.82×	-34.8%